Momentum grows for argenx’s Vyvgart

The bull case for Vyvgart efgartigimod becoming a blockbuster drug continues to grow after argenx reported positive Phase III data for the molecule’s second indication, CIDP, with readouts in a third and fourth expected this year.

Investors appear to agree, as they added $5.9 billion to the market cap of argenx SE (Euronext:ARGX; NASDAQ:ARGX) as shares climbed $105.35 (28%) to $484.43 on Monday, with an intra-day 52-week high of $498.63. The move put the Dutch company’s market cap at $27 billion...